Company news
Regenxbio Inc. (NASDAQ:RGNX) news
Regenxbio Inc. news releases on 6ix. Latest, Sep 24, 2026: REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic…
Press releases & updates
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
September 24, 2026
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
August 25, 2026
REGENXBIO : Announces Regulatory Update on RGX-121 for MPS II
August 24, 2026
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
August 24, 2026
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
August 6, 2026
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
August 3, 2026
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
July 18, 2026
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
July 17, 2026
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
June 29, 2026
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
June 24, 2026
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
June 22, 2026
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
May 13, 2026
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
May 7, 2026
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
May 6, 2026
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
March 10, 2026
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
March 4, 2026
REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 4, 2026
REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
February 25, 2026
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
February 9, 2026
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
January 28, 2026
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
January 10, 2026
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
REGENXBIO to Participate in Upcoming Investor Conference
November 24, 2025
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
November 5, 2025
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
October 29, 2025
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
October 28, 2025
REGENXBIO to Participate in Upcoming Investor Conferences
October 14, 2025
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
October 8, 2025
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
October 5, 2025
REGENXBIO Announces Presentation at the World Muscle Society
September 28, 2025
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
September 4, 2025
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
August 17, 2025
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
August 6, 2025
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
August 6, 2025
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
July 30, 2025
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
July 9, 2025
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
June 4, 2025
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
June 1, 2025
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
May 18, 2025
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
May 14, 2025
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
May 12, 2025
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
May 11, 2025
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
May 7, 2025
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
April 29, 2025
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
March 18, 2025
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
March 12, 2025
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 9, 2025
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
March 3, 2025
REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
February 25, 2025
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
January 29, 2025